825 related articles for article (PubMed ID: 16231250)
1. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
[TBL] [Abstract][Full Text] [Related]
3. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
[TBL] [Abstract][Full Text] [Related]
4. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
5. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
[TBL] [Abstract][Full Text] [Related]
6. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
Wilcox M; Nathwani D; Dryden M
J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin: a review for dermatologists.
Scheinfeld N
Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
[TBL] [Abstract][Full Text] [Related]
8. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B
Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695
[TBL] [Abstract][Full Text] [Related]
9. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children.
Wible K; Tregnaghi M; Bruss J; Fleishaker D; Naberhuis-Stehouwer S; Hilty M
Pediatr Infect Dis J; 2003 Apr; 22(4):315-23. PubMed ID: 12690270
[TBL] [Abstract][Full Text] [Related]
10. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C
Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714
[TBL] [Abstract][Full Text] [Related]
11. Linezolid for the treatment of complicated skin and skin structure infections in children.
Yogev R; Patterson LE; Kaplan SL; Adler S; Morfin MR; Martin A; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.
Raad I; Darouiche R; Vazquez J; Lentnek A; Hachem R; Hanna H; Goldstein B; Henkel T; Seltzer E
Clin Infect Dis; 2005 Feb; 40(3):374-80. PubMed ID: 15668859
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
14. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
[TBL] [Abstract][Full Text] [Related]
15. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
16. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
17. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
Rubinstein E; Cammarata S; Oliphant T; Wunderink R;
Clin Infect Dis; 2001 Feb; 32(3):402-12. PubMed ID: 11170948
[TBL] [Abstract][Full Text] [Related]
18. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
20. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]